Compound DNA vaccine encoding SAG1/ SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii

Cong, Hua; Zhang, Min; Qing, Xin; Wang, Zhiyu; Li, Ying; Zhao, Qian; Zhou, Huaiyu; He, Shenyi

doi:10.1186/1756-3305-6-63

Cited by 40 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in agreement with Zaharoff et al (2007) who used b-galactosidase vaccine in either chitosan solution or FIA and reported no significant difference between them. A significant increase in IFN c level was also obtained by Meng et al (2012), Chuang et al (2013), Zhao et al (2013a) and Cong et al (2013).…”

Section: Discussionmentioning

confidence: 74%

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

et al. 2014

View full text Add to dashboard Cite

Toxoplasmosis, a zoonotic parasitic disease, is a huge challenge for which there is no effective vaccine up till now. In this study, chitosan nanospheres encapsulated with Toxoplasma lysate vaccine was evaluated for its ability to protect mice against both acute and chronic toxoplasmosis models of infection. Results showed that chitosan nanospheres were equally effective to Freund's incomplete adjuvant (FIA) in enhancing the efficacy of Toxoplasma lysate vaccine. The effectiveness was demonstrated by the delayed death of vaccinated mice following challenge either with virulent RH or avirulent Me49 strains, the significant decrease in parasite density in different organs, significant increase in the humoral and cellular immune response (IgG and IFN c) with a marked reduction of pathological changes in the different organs. However chitosan nanospheres were superior to FIA due to their cost effective preparation and much less necrotic changes induced in the studied organs. The success of chitosan polymer as an alternative to commonly used adjuvants paves the way for the use of other newly developed polymers to be used in the field of vaccine development.

show abstract

Section: Discussionmentioning

confidence: 74%

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The levels of cytokines were detected by a previously described method (Cong et al, 2013). Four weeks after the last booster vaccination, spleens were isolated from euthanized mice (three mice per group).…”

Section: Spleen Cell Cultures and Cytokine Quantificationmentioning

confidence: 99%

Evaluation of immune responses induced by rhoptry protein 5 and rhoptry protein 7 DNA vaccines against Toxoplasma gondii

Wang

Lü

Zhou

et al. 2016

Parasite Immunology

View full text Add to dashboard Cite

Infection with the protozoan parasite Toxoplasma gondii is widespread, and the organism can cause congenital infections in humans. The horizontal transmission of Toxoplasma is even more common than congenital. An effective vaccine strategy brings the prospect of improving Toxoplasma disease control. Rhoptry protein 5 (ROP5) and ROP7 are potential stimulators of humoral and cellular immune responses. In this study, we constructed a multi-antigenic DNA vaccine expressing ROP5 and ROP7 of T. gondii and compared the protective efficacy to single-gene vaccines and control groups. BALB/c mice were immunized intramuscularly three times. The levels of IgG antibodies and cytokines in mice immunized with the multi-antigenic DNA vaccine (pROP5/ROP7) were significantly higher than those in the control mice. Mice vaccinated with pROP5/ROP7 showed a longer survival time (16 days) than single-gene-immunized mice (11 and 12 days, respectively) or control mice (8 days) after a challenge with 1 × 10(4) tachyzoites of RH strain of T. gondii. Furthermore, after intragastric infection with 20 cysts of PRU strain of T. gondii, the number of brain cysts in mice immunized with pROP5/ROP7 was only 25% of the number in control mice. Our results showed that a DNA vaccine encoding ROP5 and ROP7 significantly enhanced protection against T. gondii challenge.

show abstract

“…The proteins produced from DNA vaccine in vivo are presented as both MHC class I and II molecules [4]. In this direction, the plasmid pcDNA3.1(+) was used as a vector for DNA vaccine construction [23,24] and proved efficient for the expression of CsAg17 protein in FVB mice.…”

Section: Discussionmentioning

confidence: 99%

Clonorchis sinensis secretory protein CsAg17 vaccine induces immune protection

et al. 2020

View full text Add to dashboard Cite

Background: Clonorchiasis is endemic in East and Southeast Asian countries. For a preventive strategy against infectious diseases, vaccination is the most effective. Here, we evaluated the molecular characteristics and immune responses of CsAg17 protein from Clonorchis sinensis, and investigated its protective effects against C. sinensis challenge. Methods: A cDNA clone encoding CsAg17 protein and containing a secretory signal peptide at the N-terminus was retrieved from the C. sinensis transcriptome bank. Recombinant CsAg17 B-cell epitope protein and cDNA vaccines were produced and their immune responses were evaluated in FVB mice. The proportional changes of CD3 + /CD4 + and CD3 + /CD8 + T cells were detected by flow cytometry, and immune effectors were measured by ELISA. Results: The CsAg17 mRNA was transcribed at a higher level in C. sinensis adults than in metacercariae. The CsAg17 protein was distributed in the sperms, oral and ventral suckers, and mesenchymal tissues of C. sinensis adults. In mice challenged with C. sinensis metacercariae, vaccination with CsAg17 protein and cDNA resulted in a reduction to 64% and 69% in worm burden, respectively. Both CsAg17 protein and cDNA vaccines increased the proportion of CD3 + / CD4 + and CD3 + /CD8 + T cells and stimulated the production of Th1 type cytokines such as interleukin (IL)-2, IL-12, and interferon-γ, while maintaining minimum levels of Th2 cytokines. The levels of IgG specific to CsAg17 protein steeply increased in the two vaccinated groups from 2 weeks after immunization. The liver tissue retained good morphology in the mice vaccinated with CsAg17 protein or cDNA, whereas severe inflammation and large serous cysts were observed in the liver of the unvaccinated mice. Conclusions: Vaccination with CsAg17 protein and cDNA reduced the pathological changes in the bile duct and liver, and ameliorated the worm burden via cellular and humoral immune responses. Thus, they may serve as good vaccine candidates against C. sinensis infections.

show abstract

Compound DNA vaccine encoding SAG1/ SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii

Cited by 40 publications

References 32 publications

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

Evaluation of immune responses induced by rhoptry protein 5 and rhoptry protein 7 DNA vaccines against Toxoplasma gondii

Clonorchis sinensis secretory protein CsAg17 vaccine induces immune protection

Contact Info

Product

Resources

About